Piper Sandler lowered the firm’s price target on Akoya Biosciences to $4 from $6 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs group following the Q2 earnings reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
- Akoya Biosciences price target lowered to $7 from $7.50 at Craig-Hallum
- Akoya Biosciences downgraded to Neutral from Buy at BTIG
- Akoya Biosciences downgraded to Neutral from Overweight at JPMorgan
- Akoya Biosciences sees FY24 revenue $96M-104M, consensus $103.2M